牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-20-002368 Act: 33 Size: 1 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-024446 Act: 34 Size: 30 KB 网页链接
$灿菲特生物制药(CANF)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001213900-20-024257 Act: 33 Size: 545 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-023935 Act: 34 Size: 1 MB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-023566 Act: 34 Size: 30 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-021628 Act: 34 Size: 11 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-020386 Act: 34 Size: 11 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-20-018636 Act: 34 Size: 25 KB 网页链接
$灿菲特生物制药(CANF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-20-001917 Act: 33 Size: 1 KB 网页链接
$灿菲特生物制药(CANF)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001213900-20-018541 Act: 33 Size: 441 KB 网页链接